FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3120005102> ?p ?o ?g. }

• W3120005102 abstract "We investigate whether the cancer sites that experienced more pharmaceutical innovation in New Zealand had larger subsequent declines in premature mortality and hospitalization rates and larger subsequent increases in 5-year survival rates, controlling for changes in incidence.We estimate the effects of the number of WHO ATC5 chemical substances and ATC4 chemical subgroups approved on the number of years of potential life lost before ages 85, 75, 65, 5-year relative survival rates, and the number of inpatient hospital discharges, by estimating difference-in-differences (2-way fixed-effects) models using aggregate longitudinal data on 23 cancer sites.Substances/subgroups approved during 1985-2001 reduced the number of years of potential life lost before age 85 (YPLL85) in 2017 by 67%. Those substances/subgroups reduced YPLL75 and YPLL65 in 2017 by similar percentages. The odds of surviving at least 5 years after diagnosis are significantly positively related to the number of substances previously approved.The cost per life-year before age 85 gained in 2017 from previous drug approvals did not exceed 1719 USD. The WHO considers interventions whose cost per quality-adjusted life-year gained is less than per capita GDP to be highly cost-effective; New Zealand's per capita GDP in 2017 was 42,260 USD. capita GDP in 2017 was 42,260 USD.Pharmaceutical innovation-the introduction and use of new drugs-substantially increased cancer survival rates in New Zealand, and substantially reduced premature (before ages 85, 75, and 65) cancer mortality there during the period 1998-2017. Moreover, overall the new cancer drugs were highly costeffective. The drugs approved during 1985-2001 are estimated to have reduced the number of years of potential life lost before age 85 in 2017 by 244,876. Even if previous drug approvals increased the cost of hospital discharges and other medical costs, the cost per life-year before age 85 gained in 2017 from those approvals could not have exceeded 1719 USD." @default.
• W3120005102 created "2021-01-18" @default.
• W3120005102 creator A5041640034 @default.
• W3120005102 date "2021-03-15" @default.
• W3120005102 modified "2023-09-25" @default.
• W3120005102 title "The impact of pharmaceutical innovation on the longevity and hospitalization of New Zealand cancer patients, 1998–2017" @default.
• W3120005102 cites W1524178776 @default.
• W3120005102 cites W2031381407 @default.
• W3120005102 cites W2050273721 @default.
• W3120005102 cites W2054383884 @default.
• W3120005102 cites W2104494483 @default.
• W3120005102 cites W2146461887 @default.
• W3120005102 cites W2155793107 @default.
• W3120005102 cites W2162484441 @default.
• W3120005102 cites W2163623879 @default.
• W3120005102 cites W2557867537 @default.
• W3120005102 cites W3124355409 @default.
• W3120005102 cites W3125527990 @default.
• W3120005102 doi "https://doi.org/10.1080/14737167.2021.1871330" @default.
• W3120005102 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33412958" @default.
• W3120005102 hasPublicationYear "2021" @default.
• W3120005102 type Work @default.
• W3120005102 sameAs 3120005102 @default.
• W3120005102 citedByCount "0" @default.
• W3120005102 crossrefType "journal-article" @default.
• W3120005102 hasAuthorship W3120005102A5041640034 @default.
• W3120005102 hasBestOaLocation W31200051021 @default.
• W3120005102 hasConcept C120665830 @default.
• W3120005102 hasConcept C121332964 @default.
• W3120005102 hasConcept C127598652 @default.
• W3120005102 hasConcept C133925201 @default.
• W3120005102 hasConcept C144024400 @default.
• W3120005102 hasConcept C149923435 @default.
• W3120005102 hasConcept C2776759703 @default.
• W3120005102 hasConcept C2908647359 @default.
• W3120005102 hasConcept C61511704 @default.
• W3120005102 hasConcept C71924100 @default.
• W3120005102 hasConcept C74909509 @default.
• W3120005102 hasConcept C99454951 @default.
• W3120005102 hasConceptScore W3120005102C120665830 @default.
• W3120005102 hasConceptScore W3120005102C121332964 @default.
• W3120005102 hasConceptScore W3120005102C127598652 @default.
• W3120005102 hasConceptScore W3120005102C133925201 @default.
• W3120005102 hasConceptScore W3120005102C144024400 @default.
• W3120005102 hasConceptScore W3120005102C149923435 @default.
• W3120005102 hasConceptScore W3120005102C2776759703 @default.
• W3120005102 hasConceptScore W3120005102C2908647359 @default.
• W3120005102 hasConceptScore W3120005102C61511704 @default.
• W3120005102 hasConceptScore W3120005102C71924100 @default.
• W3120005102 hasConceptScore W3120005102C74909509 @default.
• W3120005102 hasConceptScore W3120005102C99454951 @default.
• W3120005102 hasLocation W31200051021 @default.
• W3120005102 hasLocation W31200051022 @default.
• W3120005102 hasOpenAccess W3120005102 @default.
• W3120005102 hasPrimaryLocation W31200051021 @default.
• W3120005102 hasRelatedWork W10228422 @default.
• W3120005102 hasRelatedWork W14433664 @default.
• W3120005102 hasRelatedWork W1564134 @default.
• W3120005102 hasRelatedWork W16600571 @default.
• W3120005102 hasRelatedWork W17121398 @default.
• W3120005102 hasRelatedWork W4489988 @default.
• W3120005102 hasRelatedWork W7334661 @default.
• W3120005102 hasRelatedWork W7811702 @default.
• W3120005102 hasRelatedWork W13244217 @default.
• W3120005102 hasRelatedWork W18863550 @default.
• W3120005102 isParatext "false" @default.
• W3120005102 isRetracted "false" @default.
• W3120005102 magId "3120005102" @default.
• W3120005102 workType "article" @default.